273 related articles for article (PubMed ID: 7920658)
1. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.
Duprez L; Parma J; Van Sande J; Allgeier A; Leclère J; Schvartz C; Delisle MJ; Decoulx M; Orgiazzi J; Dumont J
Nat Genet; 1994 Jul; 7(3):396-401. PubMed ID: 7920658
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
4. Constitutively activating mutations of the thyrotropin receptor and thyroid disease.
Führer D; Holzapfel HP; Wonerow P; Paschke R
Eur J Med Res; 1996 Jul; 1(10):460-4. PubMed ID: 9438142
[TBL] [Abstract][Full Text] [Related]
5. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
[TBL] [Abstract][Full Text] [Related]
7. [Non-autoimmune hyperthyroidism and hyperfunctioning thyroid adenomas caused by activating mutation of the thyrotropin receptor].
Kosugi S
Nihon Rinsho; 2002 Feb; 60(2):291-6. PubMed ID: 11857916
[TBL] [Abstract][Full Text] [Related]
8. Pathology of the TSH receptor.
Duprez L; Parma J; Van Sande J; Rodien P; Sabine C; Abramowicz M; Dumont JE; Vassart G
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():295-302. PubMed ID: 10698593
[TBL] [Abstract][Full Text] [Related]
9. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5.
Karges B; Krause G; Homoki J; Debatin KM; de Roux N; Karges W
J Endocrinol; 2005 Aug; 186(2):377-85. PubMed ID: 16079263
[TBL] [Abstract][Full Text] [Related]
10. [Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism].
Derwahl M
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():25-8. PubMed ID: 10355046
[TBL] [Abstract][Full Text] [Related]
11. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
12. Lack of in vitro constitutive activity for four previously reported TSH receptor mutations identified in patients with nonautoimmune hyperthyroidism and hot thyroid carcinomas.
Jaeschke H; Mueller S; Eszlinger M; Paschke R
Clin Endocrinol (Oxf); 2010 Dec; 73(6):815-20. PubMed ID: 20846293
[TBL] [Abstract][Full Text] [Related]
13. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
[TBL] [Abstract][Full Text] [Related]
14. Subclinical hyperthyroidism due to a thyrotropin receptor (TSHR) gene mutation (S505R).
Pohlenz J; Pfarr N; Krüger S; Hesse V
Acta Paediatr; 2006 Dec; 95(12):1685-7. PubMed ID: 17129985
[TBL] [Abstract][Full Text] [Related]
15. Premature birth and low birth weight associated with nonautoimmune hyperthyroidism due to an activating thyrotropin receptor gene mutation.
Vaidya B; Campbell V; Tripp JH; Spyer G; Hattersley AT; Ellard S
Clin Endocrinol (Oxf); 2004 Jun; 60(6):711-8. PubMed ID: 15163335
[TBL] [Abstract][Full Text] [Related]
16. Point mutations of the thyrotropin receptor determining structural requirements for its ability to bind thyrotropin and to stimulate adenylate cyclase activity.
Gustavsson B; Westermark B; Heldin NE
Biochem Biophys Res Commun; 1994 Mar; 199(2):612-8. PubMed ID: 8135801
[TBL] [Abstract][Full Text] [Related]
17. New pathophysiological mechanisms for hyperthyroidism.
Vassart G
Horm Res; 1997; 48 Suppl 4():47-50. PubMed ID: 9350447
[TBL] [Abstract][Full Text] [Related]
18. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia.
Tonacchera M; Van Sande J; Cetani F; Swillens S; Schvartz C; Winiszewski P; Portmann L; Dumont JE; Vassart G; Parma J
J Clin Endocrinol Metab; 1996 Feb; 81(2):547-54. PubMed ID: 8636266
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism.
Führer D; Wonerow P; Willgerodt H; Paschke R
J Clin Endocrinol Metab; 1997 Dec; 82(12):4234-8. PubMed ID: 9398746
[TBL] [Abstract][Full Text] [Related]
20. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
Castro I; Lima L; Seoane R; Lado-Abeal J
Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
